Possible reactivation of chromosomally integrated human herpesvirus 6 after treatment with histone deacetylase inhibitor

Ioannis Politikos(Beth Israel Deaconess Medical Center), Vassiliki A. Boussiotis(Beth Israel Deaconess Medical Center), Christine R. Bryke(Beth Israel Deaconess Medical Center), David Avigan(Beth Israel Deaconess Medical Center), Malgorzata McMasters(Beth Israel Deaconess Medical Center)
Blood Advances
June 13, 2018
10.1182/bloodadvances.2018015982
Cited by 18

Related Papers

PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|3k
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
|The Lancet|2021|1.7k
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
|New England Journal of Medicine|2016|1.4k
PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation
|Nature Communications|2015|1.2k
Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
|New England Journal of Medicine|2011|1.1k